JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB38464

Anti-VEGF Receptor 2 (phospho Y1175) antibody

Be the first to review this product! Submit a review

|

(4 Publications)

Rabbit Polyclonal VEGF Receptor 2 phospho Y1175 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 4 publications.

View Alternative Names

CD309, FLK1, VEGFR2, KDR, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, FLK-1

1 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 (phospho Y1175) antibody (AB38464)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 (phospho Y1175) antibody (AB38464)

ab38464 at a 1 : 50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using immunohistochemistry, Paraffin Embedded Tissue.

Left image : untreated.

Right image : treated with phosphopeptide.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody is specific for VEGF Receptor 2 only when phosphorylated at Tyrosine 1175. Customer feedback suggests the antibody does not work in rat or mouse tissue.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 2 also known as KDR or Flk-1 is a receptor tyrosine kinase important for mediating the effects of vascular endothelial growth factor (VEGF). This protein has a mass of approximately 150 kDa. It mostly expresses in vascular endothelial cells playing a primary role in the formation of blood vessels. The receptor can also be found in various non-endothelial tissues though in smaller amounts indicating its broad functional roles outside of the vascular system.
Biological function summary

VEGF Receptor 2 is important for angiogenesis and vascular permeability. It is part of the VEGF receptor family which also includes VEGF Receptors 1 and 3 forming a complex interaction network. Upon binding with VEGF it phosphorylates key proteins to initiate signals that regulate endothelial cell migration proliferation and survival. The receptor's function is critical for normal developmental processes and wound healing as well.

Pathways

VEGF Receptor 2 is especially important within the angiogenesis and vascular permeability pathways. It plays a central role in the VEGF signaling pathway alongside proteins like VEGF A which is the primary ligand for the receptor. The signaling through this receptor modulates various downstream proteins through phosphorylation linking it to pathways that control cellular responses essential for blood vessel formation and maintenance.

VEGF Receptor 2 is significantly linked with cancer and age-related macular degeneration. In the context of cancer the overexpression or dysregulation of VEGF and its receptors including VEGF Receptor 2 often leads to enhanced tumor angiogenesis promoting tumor growth and metastasis. Additionally the receptor interacts with other proteins in pathological states such as CD309 in endothelial cell-based assays which are used for research like flow cytometry and ELISA to monitor VEGF Receptor 2 activity and its impact on diseases.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
See full target information KDR phospho Y1175

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 10:4904 PubMed32184452

2020

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

E Sun Paik,Tae-Hyun Kim,Young Jae Cho,Jiyoon Ryu,Jung-Joo Choi,Yoo-Young Lee,Tae-Joong Kim,Chel-Hun Choi,Woo Young Kim,Jason K Sa,Jin-Ku Lee,Byoung-Gie Kim,Duk-Soo Bae,Hee Dong Han,Hyung Jun Ahn,Jeong-Won Lee

Nature communications 7:11455 PubMed27126736

2016

RhoA determines lineage fate of mesenchymal stem cells by modulating CTGF-VEGF complex in extracellular matrix.

Applications

IHC (PFA fixed)

Species

Unspecified reactive species

Changjun Li,Gehua Zhen,Yu Chai,Liang Xie,Janet L Crane,Emily Farber,Charles R Farber,Xianghang Luo,Peisong Gao,Xu Cao,Mei Wan

Stem cells translational medicine 5:218-26 PubMed26702126

2015

Intravenous Administration of Endothelial Colony-Forming Cells Overexpressing Integrin β1 Augments Angiogenesis in Ischemic Legs.

Applications

IHC

Species

Mouse

Kazuko Goto,Genzou Takemura,Tomoyuki Takahashi,Hideshi Okada,Hiromitsu Kanamori,Itta Kawamura,Takatomo Watanabe,Kentaro Morishita,Akiko Tsujimoto,Nagisa Miyazaki,Hiroaki Ushikoshi,Masanori Kawasaki,Atsushi Mikami,Ken-ichiro Kosai,Shinya Minatoguchi

Cancer prevention research (Philadelphia, Pa.) 3:1493-502 PubMed20978113

2010

Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.

Applications

IHC-P

Species

Mouse

Guolin Zhou,Rifat Hasina,Kristen Wroblewski,Tanmayi P Mankame,Colleen L Doçi,Mark W Lingen
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com